Vetter Pharma International GmbH
Ravensburg, Germany
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Vetter Pharma International GmbH
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Ravensburg, Germany
- Modalities
- Sterile Fill-Finish (syringes, vials, cartridges), Aseptic Injectable Manufacturing, Clinical Manufacturing, Commercial Filling, Drug Product Development, Assembly & Secondary Packaging, Prefilled Drug-Delivery Systems, Oligonucleotides (fill-finish), Monoclonal Antibodies (fill-finish), Biologics Injectables
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Vetter Pharma International GmbH
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSterile Fill-Finish (syringes, vials, cartridges), Aseptic Injectable Manufacturing, Clinical Manufacturing, Commercial Filling, Drug Product Development, Assembly & Secondary Packaging, Prefilled Drug-Delivery Systems, Oligonucleotides (fill-finish), Monoclonal Antibodies (fill-finish), Biologics Injectables
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (10 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (10 modalities)
Recent News 10 articles
Vetter Once Again Named Best Managed Company - European Biotechnology Magazine
Vetter Starts Construction of a New Production Site in Germany - Business Wire
Leadership Transition at Vetter: Thomas Otto Retires - Business Wire
Vetter Strengthens its Global Clinical Manufacturing Network with Strategic Site Enhancements - Business Wire
Pharmaceutical Service Provider Vetter Pharma to Build New Manufacturing Site in Germany - Business Wire
Vetter Strengthens Senior Management Team for Further Sustainable Growth - Business Wire
Vetter Recognized as 2026 CDMO Leadership Awards Winner - Business Wire
Vetter Recognized as 2026 CDMO Leadership Awards Winner - Contract Pharma
Vetter Announces Plan to Build Manufacturing Site in Germany with €1.5 Billion CDMO Investment - PharmTech.com
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony - Business Wire
Frequently Asked Questions About Vetter Pharma International GmbH
What is Vetter Pharma International GmbH's CDMO Signal Score?
Vetter Pharma International GmbH has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Vetter Pharma International GmbH for a manufacturing program?
Use the free AI matchmaker to compare Vetter Pharma International GmbH against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: